RFK Jr., The FDA, and the Future of Peptides: What Could Change for BPC-157, TB-500, CJC-1295 and More

In this episode we explore the growing conversation around Robert F. Kennedy Jr. and the possibility of several peptides being reconsidered within the FDA regulatory system. Many peptides that were once available through compounding pharmacies were restricted in recent years, leaving physicians and patients without access through traditional medical channels.

We break down the peptides frequently discussed in these regulatory conversations, including BPC-157, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu, Thymosin Alpha-1, Epitalon, KPV, LL-37, Kisspeptin-10, Melanotan II, Dihexa, and Mechano Growth Factor. We talk about what these peptides do, why they were restricted, and what potential regulatory changes could mean for the future of peptide therapy.

This episode also dives into the larger discussion about innovation, patient access, compounding pharmacies, and the evolving role of peptides in regenerative medicine, longevity science, metabolic health, and recovery.

Whether you are new to peptides or have been following the regulatory landscape for years, this episode gives you a clear overview of what is being discussed, what could change, and why it matters.